Lisdexamfetamine

Lisdexamfetamine Reactions 1680, p205 - 2 Dec 2017 Exacerbation of haematophobia and syncope: case report A 19-year-old woman developed exacerbation of haematophobia and syncope during treatment with lisdexamfetamine [route, times to reactions onsets and outcomes not stated]. The woman had attention deficit hyperactivity disorder including depression and obsessions, and a life-long haematophobia. She used to feel presyncopal with blood draws. Various examinations were performed. Base on the finding of these examinations, she was started on lisdexamfetamine 20 mg/day. A notable improvement was seen in the symptoms of attention deficit hyperactivity disorder along with resolution of her depression, anxiety and obsessions. However, a significant exacerbation of her haematophobia was noted concurrently. This exacerbation manifested as an elevated emotional and physiological response. Syncope was seen on phlebotomy with recurrent haematophobia-induced syncope, for which she required a visit to the emergency department. Author comment: "Lisdexamfetamine, a prodrug of dextroamphetamine, used in the treatment of attention deficit hyperactivity disorder and binge eating disorder, has been described to exacerbate a plethora of psychiatric disorders." However, this patient’s hematophobia and associated syncope were exacerbated, the mechanism by which is unclear." Chand MR, et al. Lisdexamfetamine augmentation of hematophobia. CNS Spectrums 22: 83 abstr. 137, No. 1, Feb 2017. Available from: URL: http:// doi.org/10.1017/S1092852916000900 [abstract] - USA 803284955 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Lisdexamfetamine

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/lisdexamfetamine-tj5Kjza2Xb
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39136-6
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial